Sign in
TerminatedPhase 2

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

Key facts

Who runs it
Weill Medical College of Cornell University
Where
New York, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
2 people enrolled
Started
22 Nov 2019
Ended
10 Jul 2024
Type of study
Interventional, 5 groups
Treatments tested
  • Vactosertib
Record updated
2 July 2025
Why it stopped
Low accrual

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients who meet the WHO 2016 criteria for a Ph-neg MPN (including PV, ET, MF, MDS/MPN, MPN-U)
  • Patients with MF must have DIPSS+ Intermediate or High-risk MF (primary of post-PV/ET)
  • For patients receiving cytoreductive therapy, they should be on a stable dose of current cytoreductive therapy for at least 3 months prior to C1D1
  • Anemia as defined by HGB < 10 g/dL, or transfusion of ≥ 2 packed red blood cell (PRBC) unit within the past 4 weeks with HGB ≤8.5g/dL
  • Ineligible, unsuitable or refractoriness to ESA therapy defined as any of the following:; Serum erythropoietin (EPO) >125 U/L; Proven ESA unsuitability is defined by history of any of the following:; Loss of erythroid hematologic improvement while receiving stable or increased ESA dose; or; ESA-attributed toxicity that, in the treating physician's opinion, makes ESA therapy unsuitable for subject; ESA refractoriness defined by lack of erythroid hematologic improvement to ESA:27; Less than 1.5 g/dL increase in hemoglobin after at least 6 weeks of ESA therapy; or; Ongoing transfusion dependence that has not been reduced by > 4U over an 8-week period compared to ESA pre-treatment 8 weeks
  • Acceptable Cardiovascular status

Who cannot take part

  • Female subjects who are breastfeeding, or intend to breastfeed, during the study or in the 30 days following the last dose of study drug are excluded
  • Any other serious medical condition which in the Investigator's opinion would preclude safe participation in the study
  • Patients with history of TIA or stroke within the past 12 months are excluded

Where in United States

  • Weill Medical College of Cornell UniversityNew York, United States

About the trial

What the trial wants to find out

This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of anemic patients with myeloproliferative neoplasms. TGFβ signaling is known to be abnormally high in patients with myeloproliferative neoplasms and it is thought that abnormal TGFβ signals cause many of the problems with blood cell formation in these diseases. The study design allows all patients to receive the study drug, vactosertib. The dose of vactosertib is individualized within a pre-set range based upon its effectiveness and tolerability. A total of up to 37 patients will be treated.

The 5 groups in the trial

  • Tier 1: Vactosertib 50 mg BIDTreatment being tested

    Vactosertib intra-patient dose finding cohort.

    Treatment: Vactosertib

  • Tier 1: Vactosertib 100 mg BIDTreatment being tested

    Treatment: Vactosertib

  • Tier 1: Vactosertib 150 mg BIDTreatment being tested

    Treatment: Vactosertib

  • Tier 1: Vactosertib 200mg BIDTreatment being tested

    Treatment: Vactosertib

  • Tier 2: VactosertibTreatment being tested

    Treatment: Vactosertib

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs)
Record updated
2 July 2025